Lower than expected risk of bone density decline with Truvada PrEP

Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use—very high adherence—had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. The study findings and the implications for the lower than expected results on the potential for broader use of Truvada in PrEP and in AIDS treatment are explored in an article published in AIDS Research and Human Retroviruses, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Matthew Spinelli, University of California, San Francisco and a large team of researchers coauthored the article entitled “Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.” Declines in bone mineral density with regular tenofovir use are an ongoing concern and may be limiting PrEP. The researchers in this study used estimated PrEP adherence data and measurements of bone density using X-ray absorptiometry (DXA). The data were gathered over a median of 24 weeks.

Source: Read Full Article

Related posts:
  1. Study links vitamin D-deficient older adults with greater risk of developing depression
  2. Factors associated with loss of usual source of care among older adults
  3. Dancing Tied to Lower Odds of Disability in Activities of Daily Living
  4. A 2-Year-Old Is in a Coma With a 50/50 Chance of Survival Because of a Severe Case of the Flu
  5. Workers who are unpaid caregivers of older relatives struggle with unmet workplace needs